Early_cellular_and_molecular_consequences_of_CEBPA_N321D_Expression_WES
Mutations involving the CEBPA gene are frequently found in AML patients. The early stages of leukaemogenic transformation are typically inaccessible from human patients and conventional mouse models. We took advantage of conditionally immortalised multipotent haematopoietic progenitor cells to develop a new CEBPA-mutant model capturing the early cellular and molecular consequences of CEBPA-N321D expression based on a clear clonal relationship between the parental and leukaemic cells. In this project, we want to identify additional mutations that could be involved in the leukaemic potential of our model in vivo by comparing cells harvested from symptomatic mice with the originally transplanted cells.